Understanding airflow limitation in asthma exacerbations
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers
This study is testing how airflow problems during asthma attacks are caused by issues in the airways of non-smoking people with moderate to severe asthma, while they are treated with inhaled medications.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 10 Years to 80 Years |
| Sex | All |
| Sponsor | Gelb, Arthur F., M.D. Indiv |
| Locations | 1 site (Lakewood, California) |
| Trial ID | NCT01225913 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the mechanisms behind expiratory airflow limitation in stable, non-smoking asthmatics with moderate to severe persistent airflow obstruction. Participants will receive inhaled corticosteroids and long-acting beta2-agonists while researchers assess whether large or small airways are primarily responsible for airflow limitation. The study will also evaluate the role of inflammation in these airways using exhaled nitric oxide as a marker. Additionally, lung function studies will be compared to pathological analyses from autopsy samples to better understand lung structure and function in asthma.
Who should consider this trial
Good fit: Ideal candidates are non-smoking individuals aged 10-80 with stable, treated asthma and significant airflow obstruction.
Not a fit: Patients who are pregnant or have a significant smoking history may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for asthma by identifying specific mechanisms of airflow limitation.
How similar studies have performed: While this study explores specific mechanisms in asthma, similar studies have shown promise in understanding airflow limitation and its treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current non-smoking (\<10 pack yr smoking history) * Stable, treated asthmatics * Age 10-80 yr * post 180ug albuterol by MDI: FEV 1/FVC \< 70% and FEV 1 \<80% predicted Exclusion Criteria: * Pregnancy
Where this trial is running
Lakewood, California
- Arthur F Gelb Medical Corporation — Lakewood, California, United States (Recruiting)
Study contacts
- Principal investigator: Arthur F Gelb, MD — Arthur F Gelb Medical Corporation
- Study coordinator: Arthur F Gelb, MD
- Email: afgelb@msn.com
- Phone: 562-633-2204
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.